Sanofi Pasteur signs research deal with nanocarrier developer
This article was originally published in Scrip
Sanofi Pasteurhas signed a research agreement with the privately held French biotechnology company In Cell Art to explore In Cell Art's nanocarrier technologies in Sanofi Pasteur's vaccine programmes. The nanocarriers form novel supramolecular groups that lead to efficient cellular and humoral responses for both prophylactic and therapeutic applications. In Cell Art hopes that if results from studies undertaken in the agreement are positive, the evaluation of its nanocarrier technologies will continue into Sanofi Pasteur's vaccine development. In Cell
You may also be interested in...
Myotec Therapeutics and Hybrid Biosystems are to merge to form PsiOxus Therapeutics with £3.6 million in funding from a syndicate led by the former's previous backer Imperial Innovations.
A Phase II efficacy and safety study of Trophos' cholesterol-oxime compound TRO40303 to treat cardiac ischaemia-reperfusion injury in acute myocardial infarction patients will be substantially underwritten by funds from the European Union, the Marseilles-based company says. Trophos is to head a new 16-partner consortium called MitoCare, a 2.5 year international translational medicine project that has received a €6 million award under the European Union Seventh Framework Programme for research. The project will begin in January 2011.
Alcon's board of directors has finally approved a merger agreement with Novartis for the Alcon shares the latter does not already own, drawing a close to protracted negotiations that first began nearly a year ago.